A well-known injectable birth control method is under fire after multiple studies linked it to a specific kind of brain tumor, and now, lawsuits are piling up against the drugmaker.
Medroxyprogesterone acetate, commonly known as Depo-Provera and administered every three months, is associated with a higher risk of developing meningiomas. According to new research in Expert Opinion on Drug Safety, women using the injection face a “significantly higher risk” compared to those on oral contraceptives.
A separate study in the British Medical Journal showed that just one year of use increased meningioma risk fivefold. Meanwhile, researchers at the University of Alabama found a “53% increased odds” of developing the tumor from injectable use, while oral forms posed no risk.
“MPA use is linked to a substantially increased risk of meningiomas, underscoring the importance of assessing its long-term use,” the study warns.
Pfizer, the manufacturer of Depo-Provera, denies wrongdoing. In a statement, the company said, “Pfizer believes these claims are without merit and will vigorously defend against these allegations.”
Meningiomas are tumors that form in the meninges, the protective layers around the brain. Though not technically brain tumors, they can cause serious health issues depending on their location.
“We have seen clients with stroke, seizure disorders, cognitive impairments, and other damages,” said attorney Chris Paulos.
With a class action underway, attorney Virginia Buchanan said, “Women deserve to have all the facts when making decisions about their health, especially when it comes to something as personal as birth control.”
